IFNAR Inhibitors
2 drugsAbout IFNAR
Interferon alpha/beta receptor (IFNAR) is a cell surface receptor complex mediating type I interferon effects, which are cytokines vital for immune responses. Binding of interferons to IFNAR triggers intracellular events, leading to the expression of genes involved in antiviral defense and immune modulation.
IFNAR is a clinically relevant target, evidenced by the FDA-approved drug BESREMI. Currently, there is no genetic evidence directly linking IFNAR variations to specific diseases, suggesting opportunities for further research.
IFNAR is targeted by one FDA-approved drug, BESREMI, a biologic (other) from PHARMAESSENTIA CORP approved in 2021. This single drug falls into the 'Other' therapeutic area, indicating potential applications beyond common disease areas.
Top IFNAR Drugs
PHARMAESSENTIA CORP is the only company with an approved drug targeting IFNAR.
Low competition suggests high market entry barriers or untapped potential for IFNAR-targeting therapies.
IFNAR Drug Modality Landscape
Modalities
Routes of Administration
IFNAR requires biologic approaches (enzyme), likely due to its structure or location.
The lack of small molecule or antibody drugs represents a whitespace opportunity for novel therapeutic modalities.
📈 Modality Evolution
other biologics pioneered IFNAR targeting (2021), with enzymes entering more recently (2021).
IFNAR Clinical Trials 40 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IFNAR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 | 100% |
| Phase 2 | 16 | 5 | 1 | 10 | 83% |
| Phase 3 | 15 | 5 | 0 | 10 | 100% |
| Phase 4 | 3 | 1 | 1 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
IFNAR Drug Approval Timeline (2021 - 2021)
BESREMI was the first and most recent drug approved for IFNAR in 2021.
Recent approval indicates renewed interest, but a single approval suggests market is not yet saturated.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 19 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IFNAR. A trial counts if an approved drug acting on IFNAR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.